10 patents currently held
83 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2031. from the record
Of the 83 now held by other companies, 82 name ModernaTX Inc. as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2031
Next term end
10
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2033 · High confidence
Also notable
Ends Mar 2033 · High confidence
Also notable
Ends Mar 2033 · High confidence
Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins
US 9,303,079
Cited by 344 later US patents, top 1% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Modified Polynucleotides for the Production of Proteins
US 9,254,311
Cited by 276 later US patents, top 1% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
In Vivo Production of Proteins
US 9,221,891
Cited by 272 later US patents, top 1% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Formerly held, still cited
Notable
Ends Mar 2033 · High confidence
Cited by 178 later US patents, top 1% of utility patents granted in 2019 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
now held by ModernaTX, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 20, 2027The maintenance fee for Modified Polynucleotides for the Production of Secreted Proteins (US 10,385,106) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Mar 10, 2027The maintenance fee for Circular Polynucleotides (US 10,407,683) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
- 1 fee due Jun 29, 2027The maintenance fee for In Vivo Production of Proteins (US 9,221,891) comes due Jun 29, 2027. Unpaid by Dec 29, 2027, it lapses early.
- 1 fee due Aug 9, 2027The maintenance fee for Modified Polynucleotides for the Production of Proteins (US 9,254,311) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.
- 1 fee due Oct 5, 2027The maintenance fee for Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins (US 9,303,079) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 10 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Alternative Nucleic Acid Molecules Containing Reduced Uracil Content and Uses Thereof | 1 in force | to Nov 2035 |
| Circular Polynucleotides | 1 in force | to Jul 2035 |
| COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAs AND METHODS OF USE | 1 in force | to Jul 2034 |
| Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins | 1 in force | to Mar 2033 |
| Modified Polynucleotides for the Production of Proteins | 1 in force | to Mar 2033 |
Patents held now
Soonest term end first.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,064,959 | Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof held by ModernaTX, Inc. In force · High confidence | In force | High confidence | |
| US 10,898,574 | Delivery and Formulation of Engineered Nucleic Acids held by ModernaTX, Inc. In force · High confidence | In force | High confidence | |
| US 9,464,124 | Engineered Nucleic Acids and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,221,891 | In Vivo Production of Proteins In force · High confidence | In force | High confidence | |
| US 9,254,311 | Modified Polynucleotides for the Production of Proteins In force · High confidence | In force | High confidence | |
| US 9,303,079 | Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins In force · High confidence | In force | High confidence | |
| US 10,385,106 | Modified Polynucleotides for the Production of Secreted Proteins held by ModernaTX, Inc. In force · High confidence | In force | High confidence | |
| US 11,027,025 | COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAs AND METHODS OF USE held by ModernaTX, Inc. In force · High confidence | In force | High confidence | |
| US 10,407,683 | Circular Polynucleotides held by ModernaTX, Inc. In force · High confidence | In force | High confidence | |
| US 9,751,925 | Alternative Nucleic Acid Molecules Containing Reduced Uracil Content and Uses Thereof held by ModernaTX, Inc. In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 10: 83 patents in force now held by others · 9 patents ended · 5 applications pending · 117 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.